Claims for Patent: 10,617,695

Summary for Patent: 10,617,695

Title:	Ophthalmic compositions containing alcaftadine
Abstract:	Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.
Inventor(s):	Ingerman; Avner (Bellmead, NJ), Janssens; Frans (Bonheiden, BE), Megens; Anton (Beerse, BE), Abelson; Mark B. (Andover, MA)
Assignee:	Vistakon Pharmaceuticals, LLC (Jacksonville, FL)
Application Number:	15/267,645
Patent Claims:	1. An ophthalmic composition, comprising: about 0.25% by weight of alcaftadine or its pharmaceutically acceptable salts. 2. The composition of claim 1, wherein the composition is in the form of a solution or suspension. 3. The composition of claim 2, wherein the pH of the composition ranges from about 6.5 to about 7.5. 4. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable topical ophthalmic vehicle. 5. The composition of claim 4, wherein the composition when administered once daily to an eye of a human subject provides a therapeutically beneficial effect in treating at least one clinical symptom of ocular allergy. 6. The composition of claim 1, wherein the composition when administered once daily to an eye of a human subject provides a therapeutically beneficial effect in treating at least one clinical symptom of ocular allergy. 7. An ophthalmic composition, comprising: a pharmaceutically acceptable ophthalmic vehicle and 0.25% by weight of alcaftadine or a pharmaceutically acceptable salt, wherein the composition when administered once daily to an eye of a human subject provides a therapeutically beneficial effect in treating at least one clinical symptom of ocular allergy. 8. The composition of claim 7, wherein the pH of the composition ranges from about 6.5 to about 7.5. 9. A method of treating ocular allergy, the method comprising administering to the eye of a patient in need thereof an effective amount of an ophthalmic composition according to claim 1, wherein the administration treats at least one clinical symptom of ocular allergy. 10. The method of claim 9, wherein the ocular allergy is allergic conjunctivitis. 11. The method of claim 9, wherein the clinical symptom is a clinical symptom of ocular inflammation. 12. The method of claim 9, wherein the clinical symptom is ocular itching, ocular redness, swelling of the eyelids, chemosis, tearing, and nasal inflammation, nasal congestion, rhinorrhea, nasal pruritis, ear prurtis, palate prurtis, or sneezing. 13. The method of claim 9, for the treatment or prevention of at least two clinical symptoms. 14. The method of claim 13, wherein the at least two clinical symptoms are ocular itching and ocular redness. 15. The method of claim 9, for the treatment or prevention of at least three clinical symptoms. 16. The method of claim 15, wherein the at least three clinical symptoms are ocular itching, ocular redness, swelling of the eyelids, chemosis, and tearing. 17. The method of claim 9, wherein the clinical symptom is a mechanistic symptom associated with ocular allergy or ocular inflammation. 18. The method of claim 17, wherein the mechanistic symptom is vascular leakage, a reduction in the integrity of the conjunctival epithelial tight junctions, modulation of the H.sub.4 receptor, or mast cell degradation. 19. The method of claim 9, wherein the clinical symptom is a nasal symptom of ocular allergy or ocular inflammation. 20. The method of claim 19, wherein the nasal symptom is nasal inflammation, nasal congestion, rhinorrhea, nasal pruritis, or sneezing.